Altogether, the aforementioned challenges must be addressed in order to decrease the perverse effects of lung cancer, especially since traditional therapeutic methods employed to obstruct lung cancer, such as chemotherapy and targeted therapy (e.g., EGFR TKIs) have in part been made obsolete by the expression of non-coding RNAs. This evidence concerns the gene EGFR and lung carcinoma.